Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.76 |
| ▸ | RXRA | P19793 | 3/20 | 0.74 |
| ▸ | RXRB | P28702 | 3/20 | 0.74 |
| ▸ | RXRG | P48443 | 2/20 | 0.74 |
| ▸ | FAAH | O00519 | 7/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327548 | 1.00 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL10247700 | 0.94 | RXRA (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL18169217 | 0.88 | RXRA (0.94) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4329559 | 0.88 | HDAC1 (0.77) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4336859 | 0.87 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL15606558 | 0.87 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL8552173 | 0.86 | RXRA (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3054236 | 0.85 | HDAC1 (0.72) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL14624038 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4335149 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765796-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8552039-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662771-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | HDAC1 3539/4885HDAC2 3806/4885HDAC3 1893/4885 |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | HDAC1 3459/4885HDAC2 3784/4885HDAC3 1890/4885 |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | HDAC1 3042/4885HDAC2 4146/4885HDAC3 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.